CAG
SUPN icon

Csenge Advisory Group’s Supernus Pharmaceuticals SUPN Stock Holding History

Csenge Advisory Group’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-17
Closed – – 1319
2018
Q3 		$0 Buy
+17
New +$839 ﹤0.01% 1571

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Csenge Advisory Group's SUPN Position: Q4 2018 in Review

Csenge Advisory Group sold out of Supernus Pharmaceuticals (SUPN) in Q4 2018, closing a stake of 17 shares.

Csenge Advisory Group first reported a position in SUPN in Q3 2018 and held it in 1 quarter. The position peaked at $0 in Q3 2018. 274 funds tracked by Wall St. Rank hold SUPN as of Q4 2018.

  • Csenge Advisory Group reported no remaining Supernus Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Csenge Advisory Group sold 17 Supernus Pharmaceuticals shares in Q4 2018.
  • Csenge Advisory Group first reported a position in Supernus Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • Csenge Advisory Group's Supernus Pharmaceuticals position peaked at $0 in Q3 2018.
  • 274 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2018.

Based on Csenge Advisory Group's 13F filing for Q4 2018, filed 7 Feb 2019.